Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

Partner | Cancer Centers | <b>Stephenson Cancer Center</b>

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

The results of the phase III FORWARD I trial showed that mirvetuximab soravtansine did not prolong progression-free survival (PFS) in the overall population of women with platinum-resistant ovarian cancer or those with folate receptor alpha (FRα)—high disease. However, this may have been due to inadequate scoring methods, explains Moore. In an exploratory analysis, investigators found a trend toward PFS in patients who were truly FRα-high.

As such, investigators relaunched a second confirmatory trial called MIRASOL, which will evaluate the agent in patients with FRα-high disease, as determined by the original scoring system used in the phase I experience. Based on the exploratory analysis and the phase I experience, investigators are hopeful that the MIRASOL trial will be positive, concludes Moore.